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saccharides and be displaced or flushed from the gastrointestinal tract.
Some intestinal pathogens, such as enteropathogenic Escherichia coli (EPEC), express multiple oligosaccharide-binding
proteins or adhesins that enable them to adhere to distinct
oligosaccharide receptor sites located at the host cell surface.
In particular, EPEC strains are model organisms for adherence
studies due to the distinctive manner in which they attach.
Ultimately, the multistep infection process generates attaching-and-effacing lesions on the brush border surface of the
small intestine (35). Lesion formation by EPEC involves an
initial nonintimate “localized adherence” (LA) characterized
by the formation of three-dimensional microcolonies, type III
secretion, and effector protein translocation to the host cell,
followed by microvillus effacement, and finally intimate attachment and pedestal formation (15, 27, 50). Recently, Cleary et
al. (8) suggested that bundle-forming pili (BFP) are primarily
responsible for initial brush border cell attachment and that
EspA filaments are probably involved in atypical EPEC attachment when BFP is absent. Thus, the initial nonintimate adherence is a key aspect of EPEC pathogenesis, since it is the first
step in infection. Preventing this initial adherence may ultimately inhibit the infection process.
Several different oligosaccharides have been shown to have
antiadhesive activity (2, 6, 13). Many of these oligosaccharides
have been isolated from natural sources, such as human breast
milk, whereas others have been synthesized based on the
known oligosaccharide components of glycolipids and glycoproteins that line the cell surface of the gastrointestinal tract.
However, the antiadhesive potential of commercially available
prebiotic oligosaccharides, some of which resemble those

Prebiotic oligosaccharides are defined as nondigestible food
ingredients that provide beneficial effects to the host by stimulating the growth of selected microbial members of the gastrointestinal tract (16). Among the colonic bacteria capable of
metabolizing prebiotic oligosaccharides and whose growth is
stimulated are species of Lactobacillus and Bifidobacterium.
The presence of these bacteria in the gastrointestinal tract has
long been associated with various health benefits (53). For
example, lactobacilli and bifidobacteria, by virtue of their ability to produce organic acids and other antagonistic agents, may
directly inhibit opportunistic pathogens (18, 48, 58). Also, enrichment of lactobacilli and bifidobacteria by prebiotics may
indirectly result in the displacement of less-desirable members
of the competing microflora (14, 17).
Recently, another mechanism by which prebiotics might interfere with and inhibit infectious bacteria has been proposed
(5, 17, 22, 26). Specifically, this model is based on the observation that certain exogenous oligosaccharides structurally resemble the receptor sites coating the intestinal epithelial cells
to which intestinal pathogens recognize and adhere (31). Accordingly, these oligosaccharides may act as molecular receptor decoys or antiadhesives that can competitively inhibit bacterial adherence. Simply stated, rather than binding to host cell
surface oligosaccharides and initiating the infection process,
the pathogen would instead bind to the soluble decoy oligo-
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Prebiotic oligosaccharides are thought to provide beneficial effects in the gastrointestinal tract of humans
and animals by stimulating growth of selected members of the intestinal microflora. Another means by which
prebiotic oligosaccharides may confer health benefits is via their antiadhesive activity. Specifically, these
oligosaccharides may directly inhibit infections by enteric pathogens due to their ability to act as structural
mimics of the pathogen binding sites that coat the surface of gastrointestinal epithelial cells. In this study, the
ability of commercial prebiotics to inhibit attachment of microcolony-forming enteropathogenic Escherichia coli
(EPEC) was investigated. The adherence of EPEC strain E2348/69 on HEp-2 and Caco-2 cells, in the presence
of fructooligosaccharides, inulin, galactooligosaccharides (GOS), lactulose, and raffinose was determined by
cultural enumeration and microscopy. Purified GOS exhibited the greatest adherence inhibition on both
HEp-2 and Caco-2 cells, reducing the adherence of EPEC by 65 and 70%, respectively. In addition, the average
number of bacteria per microcolony was significantly reduced from 14 to 4 when GOS was present. Adherence
inhibition by GOS was dose dependent, reaching a maximum at 16 mg/ml. When GOS was added to adhered
EPEC cells, no displacement was observed. The expression of BfpA, a bundle-forming-pilus protein involved
in localized adherence, was not affected by GOS, indicating that adherence inhibition was not due to the
absence of this adherence factor. In addition, GOS did not affect autoaggregation. These observations suggest
that some prebiotic oligosaccharides may have antiadhesive activity and directly inhibit the adherence of
pathogens to the host epithelial cell surface.
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TABLE 1. Structure and composition of commercial
oligosaccharides used in this study
Oligosaccharide

Chemical structure

Inulin (Inu-S)
Raftiline HP (Inu-O)
Nutraflora (GFn)
Raftilose P95 (FFn)

␣-Glu-(132)-[␤-Fru-(132)]⬎20
␣-Glu-(132)-[␤-Fru-(132)]⬎20
␣-Glu-(132)-[␤-Fru-(132)]2-4
␤-Fru-(132)-[␤-Fru-(132)]1-10 and
␣-Glu-(132)-[␤-Fru-(132)]2-10
␤-Gal-(134)-␤-Fru
␣-Gal-(136)-␣-Glu-(132)-␤-Fru
␣-Glu-(134)-[␤-Gal-(136)]2-4

Lactulose
Raffinose
Oligomate (GOS)
a
b

Composition
(%)a
95
100
97
75 and 25
95
98
100b

From the manufacturer.
After purification.

MATERIALS AND METHODS
Prebiotic oligosaccharides. The prebiotic oligosaccharides used in the present
study are described in Table 1. They include galactooligosaccharides (GOS;
purified from Oligomate 55 [Yakult, Tokyo, Japan]), raffinose (Sigma Chemical
Co., St. Louis, MO), and four fructan-type oligosaccharides: inulin (Sigma),
Raftiline HP (an inulin-containing product produced by Orafti Active Food
Ingredients, Tienen, Belgium), Nutraflora (FOS; GTC Nutrition Company,
Westminster, CO), and Raftilose P95 (Orafti). The inulin obtained from Sigma
(Inu-S) and from Orafti (Inu-O) are both extracted from chicory root and vary
in the degree of polymerization only slightly, with both averaging more than 23
fructose monomers per molecule. Nutraflora is synthesized enzymatically to
generate fructooligosaccharide (FOS) species consisting of a glucose (G) monomer linked to two, three, or four fructose (F) molecules. This product is referred
to as the GFn type of FOS. In contrast, Raftilose P95 is derived by partial
hydrolysis of inulin, yielding an FOS product containing ca. 75% of fructose-only
chains (FFn) with degrees of polymerization ranging from 2 to 7. The balance
(ca. 25%) is of the GFn form. The disaccharide, lactulose (Sigma), and the
trisaccharide, raffinose (Sigma), were also used due to their known activity as
prebiotics (9).
GOS purification. Commercial GOS, Oligomate 55, contains 55% GOS with
glucose, galactose, and lactose making up the remaining 45%. Because the latter
sugars could interfere with adherence assays, the Oligomate 55 was purified by
size exclusion chromatography using Sephadex G-10 (Sigma). Fractions were
eluted with distilled water, and those that contained carbohydrate were identified
by using a refractometer (Bausch & Lomb, Rochester, NY). Portions were
applied to aluminum-backed silica gel 60 thin-layer chromatography plates
(Whatman, Ltd., Kent, England). The plates were developed by using 1-butanol–
2-propanol–water (3:12:4, by volume) and sprayed with 50% ethanolic sulfuric
acid and heated to 115°C for 5 min to detect carbohydrates. The oligosaccharidecontaining fractions (retention factor [Rf] of ca. 0.30 to 0.67), free of mono- and
disaccharides (Rf of ⬎0.75), were then pooled and lyophilized (FTS Systems,
Inc., Stone Ridge, NY).
Bacterial strains and culture conditions. EPEC strain E2348/69 (O127:H6)
and its isogenic bfpA mutant, UMD901, were obtained from M. Donnenberg
(University of Maryland School of Medicine, Baltimore). Prior to each experiment, a freezer stock was plated onto tryptic soy agar (TSA; Difco, Detroit, MI)
with glucose and grown overnight at 37°C. A single colony was inoculated into 4
ml of tryptic soy broth without glucose (TSB; Difco) and incubated overnight at
37°C without shaking. After the overnight incubation, the cultures were inoculated at 1% (vol/vol) into Dulbecco modified Eagle medium (DMEM; GibcoBRL, Grand Island, NY) supplemented with HEPES buffer that was preequilibrated overnight in tissue culture conditions (CO2 incubator set at 5% CO2 and
95% air and 95% relative humidity). Cells were incubated 80 min in DMEM
prior to the start of each experiment to induce the genes necessary for localized
adherence (57).
Tissue culture conditions. HEp-2 (CCL-23) and Caco-2 cells (HTB37) were
obtained from the American Type Culture Collection (Manassas, Virginia) and
maintained under tissue culture conditions in minimal essential medium (GibcoBRL) supplemented with 10% fetal bovine serum (Gibco-BRL), and minimal

essential medium supplemented with 20% fetal bovine serum, respectively. For
the inhibition assays, subconfluent monolayers of HEp-2 cells were harvested
with 0.25% (vol/vol) trypsin in FC buffer (0.14 M NaCl, 5.0 mM KCl, 20.0 mM
Tris-HCl, 5.0 Tris base, 0.5 mM EDTA [pH 7.2]) and seeded onto 12-mmdiameter glass coverslips in 24-well tissue culture plates at approximately 5 ⫻ 104
HEp-2 cells per well. Plates were incubated under tissue culture conditions at
37°C for use in experiments the following day. Fourteen- to fifteen-day-postconfluent monolayers of Caco-2 cells were prepared in 24-well tissue culture dishes,
as described previously (8, 33), with or without 12-mm-diameter coverslips,
except that seeding was at 3.6 ⫻ 105 viable cells per well. The growth medium was
replaced every other day until their use in assays.
HEp-2 inhibition assays. EPEC E2348/69 and subconfluent HEp-2 cells were
prepared as described above. Inhibition assays were modified slightly from those
reported previously (55). Briefly, mannose was added to 4 ml of a previously
prepared bacterial culture at a final concentration of 1% (vol/vol) to inhibit type
I-mediated bacterial attachment (9). Each prebiotic was added at a final concentration of 16 mg/ml immediately before the assay, unless otherwise indicated.
After washing the tissue culture monolayers with phosphate-buffered saline
(PBS), 900 l of the supplemented bacterial culture (containing ca. 107 cells) was
added to each well. Tissue culture plates were incubated at 37°C in a CO2
incubator for 30 min. Preliminary experiments revealed that a 30-min incubation
time was sufficient to measure initial adherence, as indicated by the formation of
microcolonies (12, 19). The wells were then washed five times with PBS to
remove nonadherent EPEC. Coverslips were fixed with methanol for 10 min,
allowed to dry, stained with Giemsa stain for 20 min, and observed under a phase
contrast microscope with the 100⫻ objective. A minimum of 100 consecutive
HEp-2 cells were observed. Cells with microcolonies of EPEC consisting of four
or more bacteria were considered positive for having an LA phenotype (57). The
number of HEp-2 cells with LA, the number of EPEC per LA microcolony, and
the number of microcolonies per HEp-2 cell were determined. Experiments were
performed in triplicate and replicated at least three times. For displacement
assays, bacteria were incubated with HEp-2 cells for various times (0 to 30 min)
before the addition of GOS. Three wells were sacrificed every 10 min after the
addition of GOS for a total of 30 min. The results were reported as a percentage
of LA on 100 consecutive HEp-2 cells counted. The experiment was performed
in triplicate and replicated three times.
Caco-2 inhibition assays. EPEC E2348/69 and 14- to 15-day-postconfluent
Caco-2 cells were prepared as described above. These assays were performed
with slight modifications from above. First, the original inoculum size was determined by plating on TSA. Second, the assays were incubated at 37°C under
tissue culture conditions for 60 min. Lastly, plate count data using wells without
coverslips and microscopy data using wells with coverslips were recorded. Caco-2
cells without coverslips were treated with 0.1% Triton X-100 (Sigma) for 20 min,
disrupted by vigorous pipetting, serially diluted, and plated on TSA. Microscopy
data was collected by examining five fields of view at ⫻100 magnification to
determine the number of LA microcolonies (ⱖ4 bacteria) present and the
number of EPEC organisms per microcolony. Experiments were performed
three times, each time in duplicate.
Determination of BfpA expression. Overnight cultures of EPEC E2348/69 in
TSB without glucose were inoculated at 1% into DMEM and incubated under
tissue culture conditions for 80 min. GOS was added at various concentrations,
followed by incubation for 1 h. As a negative control, the bfpA mutant, UMD901
(10), was grown in LB with nalidixic acid (100 g/ml), pelleted by centrifugation,
resuspended in DMEM, and incubated for 1 h under tissue culture conditions
along with the other samples. Cultures were then pelleted by centrifugation at
2,500 ⫻ g for 5 min and resuspended in 350 l of 1% sodium dodecyl sulfate
(SDS). Next, 150 l was added to 50 l of 4⫻ SDS gel electrophoresis sample
buffer (0.25 M Tris-HCl [pH ⫽ 6.8], 8% SDS, 40% [vol/vol] glycerol, 0.0008%
bromophenol blue, 50 mM dithiothreitol). Samples were denatured by boiling
for 10 min. Then, 5 g of total protein (per lane) was loaded onto a 15%
polyacrylamide gel and separated by electrophoresis. Protein concentrations
were determined by the bicinchoninic acid protein assay kit (Pierce, Rockford,
IL). Samples were transferred to Immobilon-P polyvinylidene difluoride membranes (Millipore, Bedford, MA). The blots were blocked with PBS containing
0.05% (vol/vol) Tween 20 (PBST) and 5% nonfat dried milk and then incubated
with polyclonal anti-BfpA (1:15,000 dilution; provided by M. Donnenberg) for
2 h at room temperature. The membranes were washed three times with PBST
and incubated with donkey anti-rabbit peroxidase-conjugated antibodies
(1:30,000 dilution) for 1.5 h at room temperature. After three washes in PBST,
the membranes were developed with enhanced chemiluminescence color development reagents according to the manufacturer (Amersham Biosciences, Pittsburgh, PA). Protein bands were visualized by exposing the membrane to Kodak
X-Omat Blue XB-1 film (Eastman-Kodak, Rochester, NY).
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found in human breast milk, have not yet been studied. Therefore, the aim of the present study was to examine the ability of
various prebiotic oligosaccharides to inhibit the adherence of
an EPEC strain to HEp-2 and Caco-2 tissue culture cell lines.
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Autoaggregation assay. Aggregation assays were performed as previously described with slight modifications (1). Overnight cultures of E2348/69 and
UMD901 grown in TSB and LB with nalidixic acid (100 g/ml), respectively,
were inoculated at 1% into 4 ml of DMEM supplemented with 15 mM HEPES
(Gibco-BRL) and incubated under tissue culture conditions for 80 min. Various
concentrations of GOS were added, and the cultures were incubated until bacterial aggregates were visible in BFP-expressing strain E2348/69. A 1-ml aliquot
of each culture was removed, and the optical density (OD) was measured at 620
nm. The samples were vigorously pipetted for 30 s each, and the OD was
measured again. The percentage increase in the OD after pipetting was reported
as a quantitative aggregation index.
Scanning electron microscopy. HEp-2 inhibition assays were performed
through the wash step to remove nonadherent bacteria as described above. After
being washed with PBS, the cells were fixed with 3% glutaraldehyde in 0.1 M
phosphate buffer for 1 h and then rinsed with PBS three times for 10 min each
time. A second fixative step was performed by incubating the cells with 1%
osmium tetroxide in 0.1 M phosphate buffer for 1 h, followed by another series
of three rinses in PBS. The sample was then dehydrated with a series of graded
ethanols (25% for 10 min, 50% for 10 min, 75% for 10 min, 95% for 10 min, and
100% ethanol for two 10-min sessions). The samples were dried by critical point
drying and sputter coated with gold particles for viewing.
Statistical analysis. Significant differences between treatments were determined by the general linear model with the least-significant-difference comparison of means at 95% confidence by using SAS version 9.1.

RESULTS
Prebiotic oligosaccharides reduce adherence of EPEC to
HEP-2 cells. Although several prebiotic sugars inhibited adherence of EPEC to HEp-2 cells, purified GOS was the most
inhibitory (P ⬍ 0.05) compared to the other oligosaccharides
tested (Fig. 1). Treatment with GOS resulted in an adherence
inhibition of 65%, compared to 45% by lactulose, 38 and 31%
by the two inulin products, respectively, and 22% by raffinose.
Little inhibition (⬍5%) was observed for the two FOS products,
Raftilose (FFn type) and Nutraflora (GFn type). However, un-

purified GOS gave a slightly higher adherence inhibition, which
may be attributed to the presence of galactose (data not shown).
When tested alone, galactose showed ca. 8% adherence inhibition. In addition, as the concentration of GOS was increased from
0 to 32 mg/ml, adherence inhibition was saturable, reaching a
plateau after 16 mg/ml (Fig. 2). In contrast, GOS did not significantly reduce the presence of EPEC microcolonies when added
10, 20, or 30 min after infection (Fig. 3).
The ability of prebiotic oligosaccharides to reduce the number of EPEC per microcolony on HEp-2 cells was also observed (Table 2 and Fig. 4). Without any additions, the average
EPEC microcolony (as observed by phase-contrast microscopy) contained about 15 bacteria. Whereas Nutraflora (GFn),
Raftilose (FFn), and galactose had no significant effect on the
number of bacteria per microcolony, Inu-O, lactulose, and
Inu-S significantly reduced microcolony size to about eight
cells per microcolony (P ⬍ 0.05). In contrast, the GOS treatment gave the greatest reduction (⬎70%), with only about four
EPEC organisms per microcolony. Although scanning electron
microscopy also revealed fewer cells per microcolony in the
GOS treatment, the microcolonies did not appear to be structurally different from the control cells (Fig. 4).
The total number of microcolonies observed per HEp-2 cell
was also measured (Table 2). These results were similar to
those described above in that GOS exhibited the greatest decrease in microcolonies per HEp-2 cell. Once again, GOS was
significantly different from the control and the remaining prebiotic oligosaccharides.
Prebiotic oligosaccharides also reduce adherence of EPEC
to Caco-2 cells. Adherence inhibition on Caco-2 cell was determined by cultural enumeration and microscopic methods.
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FIG. 1. Inhibition of E2348/69 adherence to HEp-2 tissue culture cells by prebiotic oligosaccharides. Bacteria were incubated with HEp-2 cells
for 30 min in the presence of 16 mg of GOS, lactulose, Inu-S, Inu-O, raffinose, galactose, FOS-FFn, or FOS-GFn/ml. The data were collected by
counting the number of HEp-2 cells of 100 with localized adherence. Different letters above the bars indicate statistically significant differences
(P ⬍ 0.05) in means (n ⱖ 9). Lines represent the standard deviations of the means.

VOL. 74, 2006

EFFECT OF PREBIOTIC OLIGOSACCHARIDES ON E. COLI

6923

By the former method, all of the oligosaccharides tested reduced the adherence of EPEC to Caco-2 cells, with inhibition
activities ranging from 40 to 70% (Fig. 5). As for the HEp-2
cells, adherence inhibition on Caco-2 cells was greatest when
GOS was present. However, inhibition by Inu-S and lactulose
were not significantly different from that by GOS. Also, the two
FOS products were the least inhibitory.

As expected, the microscopic results for Caco-2 inhibition
assays were similar to the cultural enumeration data, except
that the overall extent of inhibition was somewhat lower.
Again, GOS had the greatest ability to reduce EPEC localized
adherence. However, all of the prebiotics except raffinose significantly reduced the ability of EPEC to adhere in a LA
pattern to Caco-2 tissue culture cells compared to the control
(Table 3). In addition to reducing the number of EPEC adhered to Caco-2 cells, GOS also reduced the average number
of bacteria per microcolony from about 14 to 6, a finding
similar to that observed for HEp-2 cells (data not shown).
GOS does not affect autoaggregation of EPEC. When EPEC
stains that express BFP are grown under tissue culture conditions, they aggregate to form large clusters that can be viewed

TABLE 2. Effect of oligosaccharides on EPEC strain E2348/69
microcolony size and formation on HEp-2 cellsa

FIG. 3. Displacement of EPEC strain E2348/69 by GOS. Bacteria
were incubated with HEp-2 cells for 60 min (}). To parallel mixtures,
GOS was added after 10 (■), 20 (Œ), and 30 min (F), as indicated by
the arrows, and incubated for an additional 30 min. The percent
adherence was determined from the number of HEp-2 cells out of 100
with localized adherence.

Oligosaccharide

Mean no. of EPEC
organisms/microcolony ⫾ SD

Mean no. of
microcolonies/
HEp-2 cell ⫾ SD

Control
Nutraflora (GFn)
Raftilose (FFn)
Galactose
Raffinose
Raftiline (Inu-O)
Inulin (Inu-S)
Lactulose
GOS

14.5 ⫾ 2.2A
13.2 ⫾ 2.1A,B
12.4 ⫾ 1.9A,B
12.2 ⫾ 1.5A,B
11.6 ⫾ 3.9B
8.6 ⫾ 3.3C
7.6 ⫾ 2.6C
8.0 ⫾ 3.8C
4.2 ⫾ 1.8D

2.0 ⫾ 0.4A
1.9 ⫾ 0.4A
2.1 ⫾ 0.3A
1.5 ⫾ 0.1B
1.4 ⫾ 0.1B
1.5 ⫾ 0.3B
1.5 ⫾ 0.1B
1.4 ⫾ 0.2B
0.9 ⫾ 0.3C

a
Values shown are means ⫾ the standard deviations (n ⫽ 9). Different superscript letters associated with values in the same column indicate statistically
significant differences (P ⬍ 0.05).
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FIG. 2. Effect of GOS concentration on the adherence inhibition of EPEC strain E2348/69 to HEp-2 cells. Lines represent the standard errors
of the means (n ⱖ 9).
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FIG. 4. Phase-contrast (A, C, D, and F) and scanning electron (B and E) micrographs showing representative fields of tissue culture cells
challenged with EPEC strain E2348/69 in the absence (A to C) and presence (D to F) of GOS (16 mg/ml). HEp-2 cells are shown in panels A,
B, D, and E; Caco-2 cells are shown in panels C and F.

microscopically and effectively quantified (1, 4). The wild-type
E2348/69 and the bfpA mutant UMD901 strains were grown
under optimal conditions for BFP expression and tested for
aggregation by measuring the OD at 620 nm of a 3-h culture
before and after vigorous agitation. The percent increase after
agitation represents the aggregation index. Table 4 shows that
the aggregation index for the wild-type strain E2348/69 was
only slightly affected by GOS. As expected, the bfpA strain was
unable to form aggregates.
Expression of EPEC BfpA is not affected by GOS. The
possibility that adherence inhibition by oligosaccharides may

be due to modulation at the genetic level, rather than physical
inhibition, has been suggested (28, 56). That is, the putative
antiadhesive oligosaccharides may repress the synthesis of adhesins, thereby accounting for the observed reduced adherence
rates. To test this hypothesis for GOS, the expression of BfpA
was examined via Western blot analysis for cells grown in the
presence or absence of GOS. No difference in BfpA expression
was found for EPEC cells, even when GOS was added at high
concentrations (Fig. 6). In addition, when HEp-2 cells that had
been infected with EPEC (grown in the presence of GOS)
were examined by scanning electron microscopy, adherence
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still occurred (albeit at lower rates than for the control) for the
GOS-treated samples (Fig. 4).
DISCUSSION
The selective manipulation of the colonic microbial population by prebiotic oligosaccharides and subsequent inhibition of
enteric pathogens within the gastrointestinal tract is generally
thought to be mediated by one of two mechanisms. First, the
metabolism of these oligosaccharides by resident lactobacilli
and bifidobacteria results in the production of organic acids
and other antagonistic agents that are inhibitory to many enteric pathogens (14, 16, 18). Second, prebiotic oligosaccharides
provide selective advantages within the highly competitive gastrointestinal tract for organisms that have the metabolic capac-

ity to utilize these nutrients at the expense of organisms that do
not (53). However, prebiotics may have a more direct effect on
pathogens within this environment. Specifically, it has been
suggested that oligosaccharides may act as antiadhesives
against bacterial adherence by mimicking the host cell receptor
sites to which intestinal pathogens recognize and adhere (31).
Our results indicate that prebiotic oligosaccharides can significantly inhibit the adherence of EPEC to tissue culture cells
due to their antiadhesive activity.
The observed differences in adherence inhibition among the
various oligosaccharides were likely due to their structural
differences. The prebiotic that had the greatest inhibitory effect
in both the HEp-2 and Caco-2 cell assays was GOS. Commercial GOS is synthesized from lactose via a transgalactosylation
reaction, yielding several GOS species containing two, three,
four, or five galactose units and a terminal glucose (11). Nat-

TABLE 3. Inhibition of localized adherence of EPEC strain
E2348/69 on Caco-2 cells by oligosaccharides
Oligosaccharide

Mean total EPEC ⫾ SDa

% Adherence
inhibitionb

Control
Raffinose (FFn)
Raftiline (Inu-O)
Nutraflora (GFn)
Lactulose
Raftilose (FFn)
Inulin (Inu-S)
GOS

160.5 ⫾ 23.8A
143.3 ⫾ 15.1A,B
131.0 ⫾ 27.3B
109.7 ⫾ 15.6C
99.3 ⫾ 21.7C,D
93.9 ⫾ 6.4C,D
92.8 ⫾ 11.3C,D
83.3 ⫾ 10.3D

11
18
32
38
42
42
48

a
That is, the mean number of microcolonies ⫾ the standard deviation (n ⫽ 6)
in five microscopic fields. Different superscript letters associated with values
indicate statistically significant differences (P ⬍ 0.05).
b
Adherence inhibition was calculated using five fields of view, as follows:
[(mean number of microcolonies of the control ⫺ mean number of microcolonies of the treatment group)/mean number of microcolonies of the control] ⫻ 100.

TABLE 4. Effect of GOS on the autoaggregation of EPEC
strain E2348/69
GOS concn
(mg/ml)

Aggregation
index ⫾ SDa

% of
wild type

E2348/69 (WT)b

0
4
8
12
16
20
24
28

49.8 ⫾ 0.03
53.2 ⫾ 0.7
52.2 ⫾ 0.3
52.9 ⫾ 2.3
56.4 ⫾ 3.3
55.0 ⫾ 1.1
55.3 ⫾ 1.4
49.6 ⫾ 0.6

100
106.8
104.9
106.1
113.2
110.5
111.0
99.5

UMD901 (bfpA)

0

1.80 ⫾ 2.5

Strain

a
b

3.6

The values shown are mean values from replicates ⫾ the standard deviation.
WT, wild type.
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FIG. 5. Inhibition of EPEC strain E2348/69 adherence to Caco-2 tissue culture cells by GOS, Inu-S, lactulose, raffinose, Inu-O, FOS-GFn, and
FOS-FFn. Bacteria were incubated with Caco-2 cells plus 16 mg of oligosaccharide/ml for 60 min. The data were collected by plate counting.
Different letters above bars indicate statistically significant differences (P ⬍ 0.05) in means (n ⫽ 6). Lines represent the standard deviations of the
means.
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FIG. 6. Effect of GOS on expression of BfpA. The bfpA mutant
strain, UMD901, was used as a negative control (lane 1). EPEC
E2348/69 was grown in DMEM with GOS at concentrations of 0 mg/ml
(lane 2), 4 mg/ml (lane 3), 8 mg/ml (lane 4), 12 mg/ml (lane 5), and 16
mg/ml (lane 6). Protein separation and immunoblot procedures were
performed as described in the text.

colony. This suggests that GOS may be targeted to the virulence factor that is responsible for microcolony formation. BFP
have been shown to mediate bacterium-bacterium interactions
and microcolony formation (20), in addition to microcolony
dispersion (4, 30). Interestingly, BFP have also been implicated
in the initial adherence of EPEC to host epithelial cells (12, 20,
54), while other studies have suggested, at least for human
intestinal organ tissue, that BFP are not involved in initial
adherence (23). Other adherence factors, such as the type III
secretion system protein EspA, flagella, the toxin lymphostatin,
and translocated protein intimin have been implicated in the
initial adherence of EPEC (3, 12, 20, 21, 29, 54). However, our
data support the role of BFP as a mediator of microcolony
formation and also as an initial adherence factor in EPEC
pathogenesis, because GOS not only reduced the number of
bacteria per microcolony, it also reduced the overall adherence
of EPEC to tissue culture cells.
Although it was expected that aggregate formation would be
reduced by GOS, autoaggregation rates of EPEC were not
affected by GOS, at least in the absence of tissue culture cells.
However, when examined microscopically, the aggregates
formed in the presence of GOS were considerably smaller and
appeared less dense, albeit more abundant, than those aggregates formed in the absence of GOS. Thus, although the expected decrease in autoaggregation by GOS did not occur, it
remains possible that GOS changed the manner in which aggregate formation occurred such that BFP-mediated adherence of EPEC was still inhibited. The possibility also exists that
adherence inhibition by GOS does occur via a decrease in
aggregate formation, but only in the presence of tissue culture
cells.
To examine the ability of GOS to displace already adhered
EPEC microcolonies, we challenged EPEC-infected HEp-2
cells with GOS at various times after infection. No matter the
length of the infection process, only slight reductions in adherence occurred. Thus, GOS may not be effective at dislodging
previously attached EPEC. In contrast, when HEp-2 cells were
incubated with GOS 30 min prior to infection with EPEC,
adherence was inhibited, albeit at a somewhat lower level than
with GOS addition at the time of infection (data not shown).
Despite the numerous reports that support the role of glycolipids, glycoproteins, and soluble oligosaccharides as molecular decoys to host cell surface oligosaccharides (2, 10, 25, 31,
32, 34, 37–39, 41, 43, 45, 46), there are also reports that suggest
that reduced adherence is due to reduced levels of adherence
proteins rather than by physical inhibition (28, 56). Our results
demonstrated, however, that the expression of BfpA was not
affected by the presence of GOS, even at high concentrations.
In addition, when tissue culture cells that had been infected
with EPEC were observed by scanning electron microscopy,
the manner in which EPEC adhered to target cells was the
same in the presence or in the absence of GOS. Noticeably,
however, the GOS-supplemented specimen showed a reduced
number of bacteria per microcolony, indicating that GOS affected the amount of adherent bacteria but not the manner in
which the adherence occurred. Thus, although we did not
measure the expression of other putative adhesins, such as
EspA and intimin, our data support the role of GOS as an
antiadhesive rather than affecting the phenotypic regulation of
BfpA-mediated adherence. Moreover, in experiments with
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urally occurring GOS with galactosyl backbones have previously been shown to inhibit adherence of pathogens (36, 40,
51). For example, human breast milk oligosaccharides have
been shown to inhibit the adherence of Campylobacter jejuni,
E. coli, Helicobacter pylori, and other pathogens to tissue culture cells (7, 38–42). These milk-borne oligosaccharides are
comprised of 12 core structures that are derived from glucose,
galactose, and N-acetylglucosamine and are often fucosylated
or sialylated (52). Several studies have attributed antiadherence activity to these fucosylated or sialylated milk oligosaccharide fractions (10, 34, 47). In the present study, relatively
high concentrations of free GOS were necessary to obtain
significant adherence inhibition. Therefore, further chemical
or enzymatic modification of GOS by fucosylation or sialylation would be expected to enhance adherence inhibition. However, other unmodified oligosaccharides, including globotriose
(Gal␣1-4Gal␤1-4Glu) and globotetraose (GalNAc␤1-3Gal␣14Gal␤1-4Glu), have been reported to inhibit the adherence of
Shiga toxins produced by enterohemorrhagic E. coli strains
that infect both humans and pigs and thus are potential antiinfective agents against these toxins (43, 44). Large-scale production of globotriose for therapeutic use against Shiga toxins
has recently been reported (59). Considering the observed
inhibitory effects of GOS, the true EPEC receptor may, therefore, contain multiple galactose (or lactose) residues, although
N-acetyllactosamine, N-acetylgalatosamine, and other modified sugar moieties are also probably involved (24, 49, 56).
Lactulose, which also reduced adherence of EPEC to both
HEp-2 and to Caco-2 cells (by 45 and 65%, respectively), is a
nondigestable disaccharide containing a single galactose moiety. However, it appears that it still may act as a molecular
mimic. Galactose, itself, had no effect, indicating that the chain
length and/or the nature of sugar linkage are important factors.
In contrast, the oligosaccharides that had the lowest adherence inhibition for both HEp-2 and Caco-2 cells were of the
FOS types (GFn and FFn). Although an in vivo study using
mice showed that dietary oligofructose (FFn) and inulin
protected female mice from the enteric pathogens Salmonella enterica serovar Typhimurium and Listeria monocytogenes, this effect was attributed to the enhanced immune
functions generated by the resident microflora rather than
to an antiadhesive activity (6).
EPEC are known for their initial adherence to tissue culture
cells, which manifests in localized adherent microcolonies that
contain four or more bacteria per microcolony (57). Our data
indicated that GOS not only reduced the adherence of EPEC
microcolonies to HEp-2 and Caco-2 cells but also had the
greatest ability to reduce the number of bacteria per micro-
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bfpA and espA mutants, a reduction in adherence with GOS
was observed only for the espA mutant, suggesting that adherence inhibition by GOS may be mediated via BfpA (data not
shown).
In summary, the results of the present study indicate that
GOS and perhaps other galactose-containing prebiotic oligosaccharides can act as antiadhesives against EPEC adherence
to intestinal epithelial cells. In addition, our data support the
role of BFP as an initial adherence factor in EPEC pathogenesis but do not rule out other possible adherence factors.
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